Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia and Schizoaffective Disorder
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.
- Trial name
- NCT00292409
- Testing
- Aripiprazole
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Schizophrenia
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder
- Trial name
- FAST (NCT00486798)
- Testing
- Quetiapine, Rating Scales, Self Assessment Form
- Where
- 13 sites in Sweden
- Sponsor
- AstraZeneca
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Schizophrenia, Schizoaffective Disorder
Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis
This randomised three-arm study aims to evaluate the efficacy and feasibility of a cognitive behavioral therapy (INT-Integrated Neurocognitive Therapy for Schizophrenia Patients) in the treatment of schizophrenia patients in an…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- CBTSZ (NCT03316664)
- Testing
- Integrated Neurocognitive Therapy (INT), Integrated Psychological Therapy (IPT), COGPACK
- Where
- Switzerland
- Volunteers
- 82 people
- Sponsor
- Psychiatric University Hospital, Zurich
Psychosis, Schizophrenia
CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia
This is a 9 week, multicentre, randomized, double-blind, placebo-controlled trial with two parallel groups. There is also an open-label extension phase of 18 weeks.
- Trial name
- NCT00272584
- Testing
- Risperidone
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Schizophrenia and Schizoaffective Disorder
A Trial of Group Cognitive Behavioral Therapy for Psychosis (the Feeling Safe Programme)
Schizophrenia is a serious psychiatric disorder characterized by delusions, hallucinations, negative symptoms and disorganized behaviour.
- Trial name
- NCT07408934
- Testing
- Cognitive Behavioral Therapy for Psychosis
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia, Schizoaffective Disorder
Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia
This is a pilot study evaluating the feasibility of a new family-based intervention for schizophrenia. It is designed to help clients diagnosed with schizophrenia to overcome the devastating effects of neurocognitive deficits on…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00434980
- Testing
- Family-Directed Cognitive Adaptation Program
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia
This study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia.
- Trial name
- CRIS (NCT00312962)
- Testing
- Targeted cognitive training (TCT), Computer games
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Schizophrenia
D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia
This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia.
- Trial name
- NCT00963924
- Testing
- D-cycloserine, Cognitive Remediation
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Schizo Affective Disorder
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
To characterize the real-life clinical use of AOM in a hospitalized patient population with schizophrenia, schizoaffective disorder or BP1 requiring LAI therapy and evaluate its short-term effectiveness associated with its…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
- Trial name
- INITIATE (NCT04907279)
- Testing
- Aripiprazole Once-Monthly (AOM)
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Otsuka Canada Pharmaceutical Inc.
Schizophrenia, Schizoaffective Disorder
Theta tACS During Working Memory Training: A Pilot Study of the Effects on Negative Symptoms of Schizophrenia
In this randomized double-blind trial, we investigated whether externally induced left-hemispheric frontoparietal theta synchronization by multi-electrode online theta (6Hz) transcranial alternating current stimulation (tACS)…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Negative Symptoms, Working Memory Training
- Trial name
- NCT04545294
- Testing
- Theta tACS
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia, Schizoaffective Disorder
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
The purpose of this study is to determine the number of Medication Treatment Modifications (MTMs) made by the clinician at every visit when antipsychotic medication plasma levels (AMPL) results are available compared to when AMPL…
- Trial name
- NCT02462473
- Testing
- Aripiprazole, Olanzapine, Paliperidone
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.
This is a screening study aimed at estimating the frequency of antipsychotic non-compliance in patients with a history of schizophrenia or other psychotic disorder admitted to an inpatient psychiatric unit.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786369
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Northwell Health
Schizophrenia, Schizoaffective Disorder
An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
The aim of this study is to evaluate the effectiveness, safety, and tolerability of metformin treatment in children and adolescents suffering from weight gain secondary to use of atypical antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder
- Trial name
- NCT00391261
- Testing
- Metformin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cambridge Health Alliance
Schizophrenia, Schizoaffective Disorder
Study of Vitamin D in the Severely Mentally Ill
Supplementation of Vitamin D in those with low levels will increase the level and result in some improvement in health and psychopathology measures.
- Trial name
- NCT01169142
- Testing
- Vitamin D3
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bronx Psychiatric Center
Schizophrenia, Schizoaffective Disorder
Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia
The purpose of this study is to determine whether individuals with schizophrenia who will take a high dose of the B-vitamins folate, B12 and pyridoxine, may experience improvement in their symptoms.
- Trial name
- NCT00403247
- Testing
- Capsule with folate, Vitamin B12 & pyridoxine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Psychotic Disorders
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity.
- Conditions
- Schizophrenia, Psychotic Disorders, Bipolar Disorder
- Trial name
- NCT00044187
- Testing
- Sibutramine
- Where
- 16 sites in United States
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Scale Validation Study for Prediction of Relapse and Short Term Rehospitalization in Patients With Schizophrenia
The purpose of this study is to establish and validate a scale/model that can be used to evaluate the duration of time and factors between short term hospital treatment and subsequent relapse periods in patients with…
- Trial name
- PRE-COG (NCT00358852)
- Testing
- No intervention
- Volunteers
- 2,339 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizo Affective Disorder
Intervention Targeting Motivational Negative Symptoms
This study aims to investigate the effects of the Switch intervention on motivation and associated processes and explore the dynamics between the processes.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- Switch (NCT04325100)
- Testing
- Switch - Individual sessions, Switch - Group programme
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- University of Liege